-
Ultimovacs ASA: Share capital increase related to exercise of options
-
Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances
-
Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
-
Ultimovacs ASA: Second quarter 2021 result presentation
-
Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma
-
Ultimovacs ASA: Invitation to second quarter 2021 results webcast presentation
-
Ultimovacs announces first patient enrolled in Phase II FOCUS trial of UV1 in head-and-neck cancer
-
Ultimovacs Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines
-
Ultimovacs’ Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines
-
Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program
